AN ACT relating to biosimilar medicines.
Summary
Amend KRS 304.17A-163 to permit insurers to require insureds to try biosimilar biological products prior to providing coverage for the equivalent branded prescription drug under certain circumstances; amend KRS 217.814 to define biosimilar biological product; amend KRS 217.822 to require dispensing of biosimilar biological products under certain circumstances.
Bill status
in committee
1 of 4 stages cleared
Introduction
Feb 2023
Committee Review
Floor Vote
Governor
Introduced Feb 16, 2023
Last action Feb 16, 2023
Floor votes
How they voted
No floor votes recorded yet.
Full legislative history
Actions timeline
Total actions
2
Key actions
0
Committee
1
Feb 16, 2023
Committee
to Committee on Committees (H)
lower
Feb 16, 2023
Introduced
introduced in House
lower
1 primary · 0 co-sponsors
Sponsors
Role
Legislator
Party
State
District
P
Kim Moser
RRepublican
Ask Maddy
·
AI policy assistant
Ask Maddy about HB 346
Scope: KY
Hi! I can help you understand HB 346. What would you like to know?
Try one of these
i
Maddy answers using official bill text and legislative records. Always verify before sharing.
Sources cited inline